Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies

NCT06823167 is registered in ClinicalTrials.gov with Immunome, Inc. as lead sponsor.

NCT NCT06823167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06823167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies
Lead sponsor
Immunome, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 26, 2025
Completion date
February 28, 2029
Enrollment
190 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies, solid malignancies